Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failu...

Full description

Bibliographic Details
Main Authors: Inga H. Rye, Anne Trinh, Anna B. Sætersdal, Daniel Nebdal, Ole Christian Lingjærde, Vanessa Almendro, Kornelia Polyak, Anne‐Lise Børresen‐Dale, Åslaug Helland, Florian Markowetz, Hege G. Russnes
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Molecular Oncology
Subjects:
breast cancer
HER2
heterogeneity
in situ analysis
outcome
therapy response
Online Access:https://doi.org/10.1002/1878-0261.12375

Internet

https://doi.org/10.1002/1878-0261.12375

Similar Items